Arkadeb D, Koushik R, Vijay K
Obesity and diabetes represent converging epidemiological crises: Fleur Pitch Semifinal for the McCloskey New Venture Competition The existing therapeutic arsenal demonstrates significant shortcomings across multiple dimensions: Mechanism: Increases insulin sensitivity and decreases hepatic glucose production Limitations: High consumption rate leading to digestive system stress, diarrhea, lactic acidosis, and vitamin B12 deficiency Mechanism: GLP-1 receptor agonists that stimulate insulin release and slow gastric emptying Limitations: Weekly injections, extended systemic half-life, neurological side effects including brain fog, optic nerve complications, depression, anxiety, and ADHD-related symptoms Mechanism: Direct insulin replacement therapy Limitations: Daily dosage requirements, off-peak effects where insulin affects blood sugar at suboptimal times Mechanism: Promotes glucose excretion through urine Limitations: Risk of urinary tract infections and dehydration Current injectable treatments represent a significant financial burden, with monthly costs ranging from $886 to $1,349: This pricing structure places effective treatment beyond the reach of many individuals who would benefit most from therapeutic intervention
You can see the changes in a matter of days
Another study by Truveta Research compared Mounjaros and Ozempics active ingredients in overweight and obese adults
